Education
About Us
Working with TipRanks
Follow Us
Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179)
:2179
RESEARCH TOOLSreports
2179 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$6.76 - HK$10.00
Previous CloseN/A
Volume13.00K
Average Volume (3M)20.72K
Market Cap
HK$4.02B
Enterprise ValueHK$9.26B
Total Cash (Recent Filing)HK$448.31M
Total Debt (Recent Filing)¥889.10M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding316,138,700
10 Day Avg. Volume13,400
30 Day Avg. Volume20,716
Financial Highlights & Ratios
PEG Ratio4.50
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-11.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Jiangsu Recbio Technology Co., Ltd. Class H News
PremiumCompany Announcements
Jiangsu Recbio Technology Announces 2024 AGM with Key Resolutions
PremiumCompany Announcements
Jiangsu Recbio to Boost Market Presence with H Share Full Circulation Plan
PremiumCompany Announcements
Jiangsu Recbio Announces Board Composition and Roles
PremiumCompany Announcements
Jiangsu Recbio Advances Vaccine Development with Promising Clinical Trials
PremiumCompany Announcements
Jiangsu Recbio Confirms Qualification of Joint Company Secretary
PremiumCompany Announcements
Jiangsu Recbio Schedules Board Meeting to Review Annual ResultsPremiumCompany Announcements
Jiangsu Recbio Technology Gains CSRC Acceptance for Share Issuance
PremiumCompany Announcements
Jiangsu Recbio’s Novel HPV Vaccine Trial Approved in China2179 FAQ
What was Jiangsu Recbio Technology Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Recbio Technology Co., Ltd. Class H lowest stock price was HK$6.76 and its highest was HK$10.00 in the past 12 months.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s market cap?
Jiangsu Recbio Technology Co., Ltd. Class H’s market cap is HK$4.02B.
When is Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date?
Jiangsu Recbio Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 21, 2025 which is in 62 days.
How were Jiangsu Recbio Technology Co., Ltd. Class H’s earnings last quarter?
Jiangsu Recbio Technology Co., Ltd. Class H released its earnings results on Mar 28, 2025. The company reported -HK$0.706 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.706.
Is Jiangsu Recbio Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangsu Recbio Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Jiangsu Recbio Technology Co., Ltd. Class H pay dividends?
Jiangsu Recbio Technology Co., Ltd. Class H does not currently pay dividends.
What is Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate?
Jiangsu Recbio Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jiangsu Recbio Technology Co., Ltd. Class H have?
Jiangsu Recbio Technology Co., Ltd. Class H has 316,138,700 shares outstanding.
What happened to Jiangsu Recbio Technology Co., Ltd. Class H’s price movement after its last earnings report?
Jiangsu Recbio Technology Co., Ltd. Class H reported an EPS of -HK$0.706 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.314%.
Which hedge fund is a major shareholder of Jiangsu Recbio Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.41%
12-Months-Change
Fundamentals
Return on Equity
-69.97%
Trailing 12-Months
Asset Growth
-14.22%
Trailing 12-Months
Company Description
Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. Class H (2179) is a biotechnology company engaged in the research, development, and commercialization of vaccines. The company focuses on innovative vaccine technologies and solutions to address unmet medical needs in infectious diseases and other areas. It operates primarily within the pharmaceutical and biotechnology sectors, offering products that aim to improve health outcomes globally.
Technical Analysis
Viva Biotech Holdings
―
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
Sinopharm Group Co
―
Wuxi Biologics (Cayman)
―